JP5144532B2 - ｃ−Ｍｅｔ阻害剤及び用法 - Google Patents

ｃ−Ｍｅｔ阻害剤及び用法 Download PDF

Info

Publication number
JP5144532B2
JP5144532B2 JP2008543461A JP2008543461A JP5144532B2 JP 5144532 B2 JP5144532 B2 JP 5144532B2 JP 2008543461 A JP2008543461 A JP 2008543461A JP 2008543461 A JP2008543461 A JP 2008543461A JP 5144532 B2 JP5144532 B2 JP 5144532B2
Authority
JP
Japan
Prior art keywords
aliphatic
compound
ring
optionally substituted
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2008543461A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009518296A5 (cg-RX-API-DMAC7.html
JP2009518296A (ja
Inventor
デイビッド ラウファー，
アレクサンダー アロノブ，
パン リー，
デイビッド デニンジャー，
キラ マギンティ，
ディーン スタモス，
ジョン カム，
ミシェル スチュワート，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of JP2009518296A publication Critical patent/JP2009518296A/ja
Publication of JP2009518296A5 publication Critical patent/JP2009518296A5/ja
Application granted granted Critical
Publication of JP5144532B2 publication Critical patent/JP5144532B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2008543461A 2005-11-30 2006-11-30 ｃ−Ｍｅｔ阻害剤及び用法 Expired - Fee Related JP5144532B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US74085905P 2005-11-30 2005-11-30
US74073705P 2005-11-30 2005-11-30
US74074105P 2005-11-30 2005-11-30
US60/740,737 2005-11-30
US60/740,859 2005-11-30
US60/740,741 2005-11-30
PCT/US2006/045847 WO2007064797A2 (en) 2005-11-30 2006-11-30 Inhibitors of c-met and uses thereof

Publications (3)

Publication Number Publication Date
JP2009518296A JP2009518296A (ja) 2009-05-07
JP2009518296A5 JP2009518296A5 (cg-RX-API-DMAC7.html) 2012-11-22
JP5144532B2 true JP5144532B2 (ja) 2013-02-13

Family

ID=37998312

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008543461A Expired - Fee Related JP5144532B2 (ja) 2005-11-30 2006-11-30 ｃ−Ｍｅｔ阻害剤及び用法

Country Status (12)

Country Link
US (2) US7728017B2 (cg-RX-API-DMAC7.html)
EP (1) EP1963329B1 (cg-RX-API-DMAC7.html)
JP (1) JP5144532B2 (cg-RX-API-DMAC7.html)
KR (1) KR20080080584A (cg-RX-API-DMAC7.html)
AU (1) AU2006320580B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0619252A2 (cg-RX-API-DMAC7.html)
CA (1) CA2630884A1 (cg-RX-API-DMAC7.html)
IL (1) IL191623A0 (cg-RX-API-DMAC7.html)
MX (1) MX2008007049A (cg-RX-API-DMAC7.html)
NO (1) NO20082880L (cg-RX-API-DMAC7.html)
NZ (1) NZ568666A (cg-RX-API-DMAC7.html)
WO (1) WO2007064797A2 (cg-RX-API-DMAC7.html)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7728013B2 (en) 2005-05-10 2010-06-01 Intermune, Inc. Method of modulating stress-activated protein kinase system
KR101412675B1 (ko) 2005-12-21 2014-07-03 얀센 파마슈티카 엔.브이. 티로신 키나제 모듈레이터로서의 트리아졸로피리다진
CA2651979A1 (en) * 2006-05-30 2007-12-06 Pfizer Products Inc. Triazolopyridazine derivatives
EP2044026B1 (en) 2006-06-22 2014-03-26 Prana Biotechnology Limited Method of treatment of glioma brain tumour
PE20080403A1 (es) * 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
US8198448B2 (en) 2006-07-14 2012-06-12 Amgen Inc. Fused heterocyclic derivatives and methods of use
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
WO2008011045A2 (en) * 2006-07-18 2008-01-24 Cytovia, Inc. 3-ARYL-6-ARYL-7H-[1,2,4]TRIAZOLO[3,4-b][1,3,4]THIADIAZINES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF
WO2008021781A1 (en) 2006-08-07 2008-02-21 Incyte Corporation Triazolotriazines as kinase inhibitors
US8481538B2 (en) 2006-09-18 2013-07-09 Vertex Pharmaceuticals Incorporated Heterocyclic inhibitors of c-Met and uses thereof
SI2497470T1 (sl) 2006-11-22 2016-02-29 Incyte Holdings Corporation Imidazotriazini in imidazopirimidini kot inhibitorji kinaz
JP5550352B2 (ja) 2007-03-15 2014-07-16 ノバルティス アーゲー 有機化合物およびその使用
CN101678014B (zh) * 2007-05-21 2012-12-12 Sgx药品公司 杂环激酶调节剂
DE102007026341A1 (de) 2007-06-06 2008-12-11 Merck Patent Gmbh Benzoxazolonderivate
US8188083B2 (en) * 2007-06-28 2012-05-29 Abbott Laboratories Triazolopyridazines
DE102007032507A1 (de) 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
FR2919870B1 (fr) * 2007-08-09 2014-05-16 Sanofi Aventis Nouveaux derives de 6-triazolopyridazine-sulfanyl benzothiazole et benzothiazole et benzimidazole, procede, compositions pharmaceutiques et nouvelle utilisation comme inhibiteurs de cmet
FR2929613B1 (fr) * 2008-04-02 2010-12-31 Sanofi Aventis Nouveaux derives de 6-triazolopyridazine-sulfanyl benzothiazole et benzimidazole,leur preparation,comme medicaments et utilisation notamment comme inhibiteurs de met
PA8792501A1 (es) * 2007-08-09 2009-04-23 Sanofi Aventis Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met.
SI2193133T1 (sl) 2007-09-27 2015-12-31 Fundacion Centro Nacional De Investigaciones Oncologicas Carlos Iii Imidazolotiadiazoli za uporabo kot zaviralci protein-kinaze
DE102007061963A1 (de) 2007-12-21 2009-06-25 Merck Patent Gmbh Pyridazinonderivate
KR20100128305A (ko) 2008-02-28 2010-12-07 노파르티스 아게 Ｃ-ｍｅｔ 티로신 키나제 매개 질환의 치료를 위한 이미다조[1,2-ｂ]피리다진 유도체
DE102008019907A1 (de) 2008-04-21 2009-10-22 Merck Patent Gmbh Pyridazinonderivate
WO2009143211A2 (en) 2008-05-21 2009-11-26 Incyte Corporation Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)- imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
US8304413B2 (en) 2008-06-03 2012-11-06 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
DE102008028905A1 (de) * 2008-06-18 2009-12-24 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
UY32049A (es) 2008-08-14 2010-03-26 Takeda Pharmaceutical Inhibidores de cmet
DE102008037790A1 (de) 2008-08-14 2010-02-18 Merck Patent Gmbh Bicyclische Triazolderivate
DE102008038221A1 (de) 2008-08-18 2010-02-25 Merck Patent Gmbh 7-Azaindolderivate
DE102008038220A1 (de) 2008-08-18 2010-02-25 Merck Patent Gmbh Oxadiazolderivate
DE102008038222A1 (de) 2008-08-18 2010-02-25 Merck Patent Gmbh Indazol-5-carbonsäurehydrazid-derivate
RU2011124894A (ru) 2008-11-19 2012-12-27 Вертекс Фармасьютикалз Инкорпорейтед Триазолотиадиазоловый ингибитор протеинкиназы с-мет
WO2010059771A1 (en) 2008-11-20 2010-05-27 Osi Pharmaceuticals, Inc. Substituted pyrrolo[2,3-b]-pyridines and-pyrazines
PA8851101A1 (es) 2008-12-16 2010-07-27 Lilly Co Eli Compuesto amino pirazol
DE102008063667A1 (de) 2008-12-18 2010-07-01 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-°[1,2,4]triazolo[4,3-b]pyrimidin-derivate
EA019320B1 (ru) 2008-12-22 2014-02-28 Мерк Патент Гмбх Новые полиморфные формы дигидрофосфата 6-(1-метил-1h-пиразол-4-ил)-2-{3-[5-(2-морфолин-4-илэтокси)пиримидин-2-ил]бензил}-2h-пиридазин-3-она и способы их получения
DE102008062825A1 (de) * 2008-12-23 2010-06-24 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo [4,3-b]pyridazin-derivate
FR2941949B1 (fr) * 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-o-cycloalkyl ou 6-nh-cycloalkyl- triazolopyridazine-sulfanyl)benzothiazoles et benzimidazoles preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941951B1 (fr) * 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-nh-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941950B1 (fr) * 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-o-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941952B1 (fr) * 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-substitue-triazolopyridazine-sulfanyl) 5-fluoro-benzothiazoles et 5-fluoro-benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
CA2749926A1 (en) 2009-02-10 2010-08-19 Astrazeneca Ab Triazolo [4,3-b] pyridazine derivatives and their uses for prostate cancer
JP2012519731A (ja) * 2009-03-09 2012-08-30 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ニコチン受容体およびｇａｂａａ受容体のアロステリックモジュレーターとしての置換複素環およびそれらの使用
CN102388055B (zh) 2009-04-02 2015-07-29 卡洛斯三世国家癌症研究中心基金会 咪唑并[2,1-b][1,3,4]噻二唑衍生物
AU2010254053A1 (en) * 2009-05-28 2011-12-01 Vertex Pharmaceuticals Incorporated Substituted pyrazole inhibitors of c-Met protein kinase
CN102448969A (zh) 2009-05-28 2012-05-09 沃泰克斯药物股份有限公司 C-met蛋白激酶抑制剂
SI2435443T1 (sl) * 2009-05-28 2013-12-31 Vertex Pharmaceuticals Incorporated Aminopirazol triazolotiadiazolni inhibitorji c-met protein kinaze
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
EP2464649A1 (en) 2009-08-12 2012-06-20 Novartis AG Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
BR112012008061A2 (pt) 2009-08-20 2016-03-01 Novartis Ag compostos de oxima heterocíclica
EP2519524A4 (en) 2009-12-31 2013-07-03 Hutchison Medipharma Ltd CERTAIN TRIAZOLOPYRIDINE AND TRIAZOLOPYRZINE, COMPOSITIONS AND METHOD OF USE
US8487096B2 (en) 2010-02-03 2013-07-16 Incyte Corporation Imidazo[1,2-B][1,2,4]triazines as C-MET inhibitors
EP2569315A1 (en) 2010-05-14 2013-03-20 OSI Pharmaceuticals, LLC Fused bicyclic kinase inhibitors
AR081039A1 (es) 2010-05-14 2012-05-30 Osi Pharmaceuticals Llc Inhibidores biciclicos fusionados de quinasa
CA2798080C (en) 2010-05-17 2020-08-25 Incozen Therapeutics Pvt. Ltd. 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases
JP2013527195A (ja) * 2010-05-27 2013-06-27 バーテックス ファーマシューティカルズ インコーポレイテッド ｃ−Ｍｅｔプロテインキナーゼのアミノピラゾールトリアゾロチアジアゾールインヒビター
EP2588107A1 (en) 2010-07-01 2013-05-08 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
AR085183A1 (es) * 2010-07-30 2013-09-18 Lilly Co Eli Compuesto 6-(1-metil-1h-pirazol-4-il)-3-(2-metil-2h-indazol-5-iltio)-[1,2,4]triazol[4,3-b]piridazina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar cancer
WO2012158658A1 (en) 2011-05-16 2012-11-22 OSI Pharmaceuticals, LLC Fused bicyclic kinase inhibitors
SG11201401531RA (en) 2011-11-11 2014-07-30 Pfizer 2-thiopyrimidinones
WO2013134562A1 (en) 2012-03-09 2013-09-12 Inception 2, Inc. Triazolone compounds and uses thereof
JP6134376B2 (ja) 2012-03-16 2017-05-24 アクシキン ファーマシューティカルズ インコーポレーテッド ３，５−ジアミノピラゾールキナーゼ阻害剤
JP6192708B2 (ja) 2012-03-30 2017-09-06 ライゼン・ファーマシューティカルズ・エスアー Ｃ−ｍｅｔプロテインキナーゼ調節物質としての新規３，５−二置換−３ｈ−イミダゾ［４，５−ｂ］ピリジン化合物および３，５−二置換−３ｈ−［１，２，３］トリアゾロ［４，５−ｂ］ピリジン化合物
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
KR102300675B1 (ko) 2012-12-20 2021-09-13 템페스트 테라퓨틱스, 인코포레이티드 트리아졸론 화합물 및 이의 용도
CA2921420A1 (en) 2013-09-06 2015-03-12 Inception 2, Inc. Triazolone compounds and uses thereof
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
WO2015046653A1 (ko) 2013-09-30 2015-04-02 한국화학연구원 신규한 트리아졸로 피라진 유도체 및 그의 용도
GB201321745D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
WO2015153683A1 (en) 2014-04-02 2015-10-08 Intermune, Inc. Anti-fibrotic pyridinones
WO2016091891A1 (en) 2014-12-09 2016-06-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Human monoclonal antibodies against axl
MY191736A (en) 2014-12-23 2022-07-13 Axikin Pharmaceuticals Inc 3,5-diaminopyrazole kinase inhibitors
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
WO2016161125A1 (en) 2015-03-31 2016-10-06 University Of Vermont And State Agricultural College Methods for treating cryptosporidiosis using triazolopyridazines
JP2018515480A (ja) 2015-05-05 2018-06-14 ファイザー・インク ２−チオピリミジノン
PH12017502322B1 (en) 2015-06-25 2023-08-30 Taiho Pharmaceutical Co Ltd Therapeutic agent for fibrosis
US20180194769A1 (en) 2015-07-06 2018-07-12 Rodin Therapeutics, Inc. Hetero-halo inhibitors of histone deacetylase
US10421756B2 (en) 2015-07-06 2019-09-24 Rodin Therapeutics, Inc. Heterobicyclic N-aminophenyl-amides as inhibitors of histone deacetylase
EP3362442B1 (en) 2015-10-14 2020-01-29 Bristol-Myers Squibb Company 2,4-dihydroxy-nicotinamides as apj agonists
EP3383860B1 (en) 2015-12-04 2021-01-20 Bristol-Myers Squibb Company Apelin receptor agonists and methods of use
MX380669B (es) 2015-12-16 2025-03-12 Bristol Myers Squibb Co Heteroarilhidroxipirimidinonas como agonistas del receptor de apelina (apj).
ES2895124T3 (es) 2016-03-24 2022-02-17 Bristol Myers Squibb Co 6-hidroxi-4-oxo-1,4-dihidropirimidin-5-carboxamidas como agonistas de APJ
GR1009565B (el) * 2016-07-14 2019-08-06 Galenica Α.Ε. Νεα παραγωγα 1,2,4-τριαζολο-[3,4-b]-1,3,4-θειαδιαζολιων
HUE057849T2 (hu) 2017-01-11 2022-06-28 Alkermes Inc Hiszton deacetiláz biciklusos gátlói
JP6771594B2 (ja) 2017-02-15 2020-10-21 大鵬薬品工業株式会社 医薬組成物
MX394399B (es) * 2017-05-26 2025-03-24 Jiangsu Atom Bioscience And Pharmaceutical Co Ltd Inhibidor de urat1 para promover la excresion de acido urico.
EP3652165B1 (en) * 2017-07-12 2021-08-25 Bristol-Myers Squibb Company Five membered-aminoheterocyclic and 5,6-or 6,6-membered bicyclic aminoheterocyclic inhibitors of rock for the treatment of heart failure
HUE058799T2 (hu) 2017-08-07 2022-09-28 Alkermes Inc Hiszton-deacetiláz biciklusos inhibitorai
EP3682882A4 (en) 2017-09-08 2021-06-02 Taiho Pharmaceutical Co., Ltd. ANTI-TUMOR AGENT AND ANTI-TUMOR POTENTIALIZER
JP7590183B2 (ja) 2018-03-13 2024-11-26 武田薬品工業株式会社 血漿カリクレインのインヒビターとしての置換されたイミダゾピリジン及びその使用
WO2021055621A1 (en) 2019-09-18 2021-03-25 Shire Human Genetic Therapies, Inc. Plasma kallikrein inhibitors and uses thereof
WO2021055589A1 (en) 2019-09-18 2021-03-25 Shire Human Genetic Therapies, Inc. Heteroaryl plasma kallikrein inhibitors
TR202009388A1 (tr) 2020-06-17 2021-12-21 Anadolu Ueniversitesi Akci̇ğer kanseri̇ tedavi̇si̇nde hedefe yöneli̇k yeni̇ tri̇azoloti̇yadi̇azi̇n türevleri̇
TR202010296A1 (tr) 2020-06-30 2022-01-21 Anadolu Ueniversitesi Akt inhibisyonu aracılığıyla a549 hücrelerinde sitotoksik ve apoptotik etki gösteren yeni triazol ve triazolotiyadiazin türevleri
EP4288430A1 (en) 2021-02-02 2023-12-13 Liminal Biosciences Limited Gpr84 antagonists and uses thereof
WO2022197789A1 (en) * 2021-03-17 2022-09-22 Shire Human Genetic Therapies, Inc. Polycyclic inhibitors of plasma kallikrein

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10038019A1 (de) 2000-08-04 2002-02-14 Bayer Ag Substituierte Triazolopyrid(az)ine
US7122548B2 (en) * 2003-07-02 2006-10-17 Sugen, Inc. Triazolotriazine compounds and uses thereof
KR101412675B1 (ko) * 2005-12-21 2014-07-03 얀센 파마슈티카 엔.브이. 티로신 키나제 모듈레이터로서의 트리아졸로피리다진

Also Published As

Publication number Publication date
NO20082880L (no) 2008-09-01
US20070191369A1 (en) 2007-08-16
US7728017B2 (en) 2010-06-01
US20100190774A1 (en) 2010-07-29
KR20080080584A (ko) 2008-09-04
NZ568666A (en) 2011-09-30
IL191623A0 (en) 2008-12-29
AU2006320580A1 (en) 2007-06-07
US7998987B2 (en) 2011-08-16
EP1963329A2 (en) 2008-09-03
CA2630884A1 (en) 2007-06-07
BRPI0619252A2 (pt) 2011-09-20
AU2006320580B2 (en) 2011-06-23
JP2009518296A (ja) 2009-05-07
MX2008007049A (es) 2008-10-23
EP1963329B1 (en) 2013-01-23
WO2007064797A3 (en) 2007-12-13
WO2007064797A2 (en) 2007-06-07

Similar Documents

Publication Publication Date Title
JP5144532B2 (ja) ｃ−Ｍｅｔ阻害剤及び用法
EP1881983B1 (en) Pyrrolopyridines useful as inhibitors of protein kinase
CA3150515A1 (en) PRMT5 INHIBITORS IN COOPERATION WITH MTA
ES2320487T3 (es) Pirrolopirimidinas utiles como inhibidores de proteina quinasas.
US20060122185A1 (en) Bicyclic inhibitors of Rho kinase
EP2001884A1 (en) Deazapurines useful as inhibitors of janus kinases
US8481538B2 (en) Heterocyclic inhibitors of c-Met and uses thereof
KR20110039383A (ko) ｃＭＥＴ 억제제
KR20110039278A (ko) 단백질 키나제 억제제
EP2252618A1 (en) PYRAZOLO [1,5-a] PYRIMIDINES USEFUL AS JAK2 INHIBITORS
JP2010508363A (ja) ヤヌスキナーゼの阻害剤として有用な三環系ヘテロアリール化合物
NZ575346A (en) 5- (2-furyl)-1, 3-thiazole derivatives useful as inhibitors of phosphatidylinositol 3-kinase
CN101360748B (zh) c-MET抑制剂及其应用
HK1125106A (en) Inhibitors of c-met and uses thereof
HK1146825A (en) Heterocyclic inhibitors of c-met and uses thereof
HK1138587A (en) Thiazoles and pyrazoles useful as kinase inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091116

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20091116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101109

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120710

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20121004

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20121030

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20121122

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20151130

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees